Raymond James & Associates Nektar Therapeutics Call Options Transaction History
Raymond James & Associates
- $161 Billion
- Q3 2024
Call Options
1 transactions
Others Institutions Holding NKTR
# of Institutions
147Shares Held
139MCall Options Held
32.6KPut Options Held
14.1K-
Deep Track Capital, LP Greenwich, CT15.9MShares$17 Million0.76% of portfolio
-
Black Rock Inc. New York, NY15.2MShares$16.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.1MShares$14 Million0.0% of portfolio
-
Eventide Asset Management, LLC Boston, MA9.4MShares$10.1 Million0.22% of portfolio
-
Samlyn Capital, LLC New York, NY9.2MShares$9.84 Million0.19% of portfolio
About NEKTAR THERAPEUTICS
- Ticker NKTR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 187,404,992
- Market Cap $201M
- Description
- Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...